Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition